Crohn's Disease Clinical Trial Landscape
Data updated: May 20, 2026
524 clinical trials tracked since 2008
Crohn's Disease is being studied across 524 clinical trials registered since 2008, with 136 programs currently active. The competitive pipeline includes 44 active Phase 3 trials, 54 active Phase 2 trials, and 24 active Phase 1 trials. Top industry sponsors include Takeda, Johnson & Johnson, AbbVie.
136 active
/
524 total (since 2008)
24
Phase 1 Active
123 total
54
Phase 2 Active
210 total
44
Phase 3 Active
151 total
32
Phase 4 Active
101 total
Top Industry Sponsors
Sorted by active Active Done Failed
Takeda 13 19 9
Johnson & Johnson 11 10 4
AbbVie 7 15 1
Eli Lilly 6 2 0
Sanofi 5 0 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT05995353 RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie n=110
NCT06332534 RECRUITING
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
AbbVie n=110
NCT06430801 RECRUITING
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Merck Sharp & Dohme LLC n=1,200
NCT06937099 RECRUITING
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company n=290
NCT05092269 ACTIVE NOT RECRUITING
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development, LLC n=159
+ 146 more Phase 3 trials — see full database below
Crohn's Disease — Trials Started by Year (last 10 years)
2016 26
2017 29
2018 38
2019 26
2020 23
2021 32
2022 26
2023 28
2024 28
2025 33
2026 22
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Takeda 41
Johnson & Johnson 25
AbbVie 23
Eli Lilly 8
Sanofi 5
Roche 9
AstraZeneca 11
Merck 3
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. 3
Direct Biologics, LLC 3
Active Trials by Phase
Phase 1 24
Phase 2 54
Phase 3 44
Phase 4 32
Enrollment Size Distribution
1-50 202
51-200 166
201-500 74
501-1k 32
1k+ 14
All Industry Sponsors
Sorted by active Active Done Failed
Takeda 13 19 9
Johnson & Johnson 11 10 4
AbbVie 7 15 1
Eli Lilly 6 2 0
Sanofi 5 0 0
Roche 4 2 3
AstraZeneca 2 6 3
Merck 2 0 1
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. 2 1 0
Direct Biologics, LLC 1 0 2
Abivax S.A. 1 0 1
Agomab Spain S.L.U. 1 1 0
Xian-Janssen Pharmaceutical Ltd. 1 0 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1 0 0
Teva Branded Pharmaceutical Products R&D LLC 1 0 0
NCT05995353 RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie n=110
NCT06332534 RECRUITING
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
AbbVie n=110
NCT06430801 RECRUITING
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Merck Sharp & Dohme LLC n=1,200
NCT06937099 RECRUITING
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company n=290
NCT07577843 NOT YET RECRUITING
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=460
NCT05092269 ACTIVE NOT RECRUITING
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development, LLC n=159
NCT05347095 ACTIVE NOT RECRUITING
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Janssen-Cilag Ltd. n=288
NCT06663332 RECRUITING
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC n=196
NCT07196722 RECRUITING
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=1,092
NCT06408935 ACTIVE NOT RECRUITING
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Janssen-Cilag Ltd. n=120
NCT05197049 ACTIVE NOT RECRUITING
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=350
NCT03466411 ACTIVE NOT RECRUITING
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=1,409
NCT07499232 RECRUITING
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=530
NCT05923073 RECRUITING
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=120
NCT05442567 RECRUITING
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda n=240
NCT06819891 RECRUITING
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=425
NCT06100289 RECRUITING
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda n=70
NCT04779320 RECRUITING
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Takeda n=120
NCT05660746 RECRUITING
Precise Infliximab Exposure and Pharmacodynamic Control
Children's Hospital Medical Center, Cincinnati n=180
NCT07184944 RECRUITING
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi n=751
NCT06819878 RECRUITING
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=600
NCT07184931 RECRUITING
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi n=980
NCT07298421 RECRUITING
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=100
NCT04844606 RECRUITING
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company n=150
NCT04524611 ACTIVE NOT RECRUITING
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
AbbVie n=527
NCT03345823 ACTIVE NOT RECRUITING
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie n=747
NCT04777656 RECRUITING
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
Assistance Publique - Hôpitaux de Paris n=120
NCT05509777 RECRUITING
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company n=90
NCT06651281 RECRUITING
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Merck Sharp & Dohme LLC n=1,380
NCT04232553 ACTIVE NOT RECRUITING
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company n=996
NCT06405087 RECRUITING
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda n=70
NCT05837897 RECRUITING
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Takeda n=408
NCT06274554 RECRUITING
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Weill Medical College of Cornell University n=120
NCT07177118 NOT YET RECRUITING
Risankizumab for Fibrostenotic Crohn's Disease Treatment
First Affiliated Hospital of Wenzhou Medical University n=260
NCT06063967 ACTIVE NOT RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie n=289
NCT03105102 ACTIVE NOT RECRUITING
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie n=1,336
NCT04997733 RECRUITING
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
Assistance Publique - Hôpitaux de Paris n=150
NCT04738942 ACTIVE NOT RECRUITING
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Takeda n=57
NCT06227910 RECRUITING
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Takeda n=396
NCT05040464 RECRUITING
Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
Centre Hospitalier Universitaire, Amiens n=166
NCT06925594 RECRUITING
Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. n=228
NCT05299931 ACTIVE NOT RECRUITING
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW n=108
NCT06719622 ENROLLING BY INVITATION
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
Medical University of Warsaw n=114
NCT04398836 NOT YET RECRUITING
Preoperative Nutrition for Crohn's Disease Patients
Tel-Aviv Sourasky Medical Center n=144
NCT04245215 COMPLETED
Loss of RESponse to Ustekinumab Treated by Dose Escalation
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW n=108
NCT02343601 COMPLETED
Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery
University Hospital, Caen n=160
NCT01233960 COMPLETED
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Mesoblast, Inc. n=73
NCT04974099 TERMINATED
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Children's Hospital Medical Center, Cincinnati n=6
NCT04397263 COMPLETED
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Pharmaceutical K.K. n=38
NCT01580670 COMPLETED
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
Tanabe Pharma Corporation n=14
NCT00805766 COMPLETED
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
Tanabe Pharma Corporation n=39
NCT02770495 COMPLETED
Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease
Hospices Civils de Lyon n=59
NCT04673357 COMPLETED
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC n=101
NCT04701411 TERMINATED
A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease
Takeda n=7
NCT03440372 TERMINATED
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Celgene n=625
NCT03464097 TERMINATED
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Celgene n=550
NCT03467958 TERMINATED
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Celgene n=854
NCT04173273 TERMINATED
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Pfizer n=375
NCT03782376 COMPLETED
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Janssen-Cilag Ltd. n=215
NCT03107793 COMPLETED
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Janssen-Cilag Ltd. n=500
NCT05784129 TERMINATED
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Janssen Research & Development, LLC n=4
NCT03464136 COMPLETED
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Janssen Scientific Affairs, LLC n=386
NCT04075825 COMPLETED
Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Takeda n=150
NCT05470985 TERMINATED
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
Bristol-Myers Squibb n=5
NCT02620046 COMPLETED
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
Takeda n=746
NCT01369355 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Janssen Research & Development, LLC n=1,282
NCT03926130 COMPLETED
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company n=1,158
NCT03440385 COMPLETED
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Celgene n=606
NCT02403323 TERMINATED
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Hoffmann-La Roche n=790
NCT04060303 COMPLETED
ENhanced Recovery in CHildren Undergoing Surgery
Northwestern University n=599
NCT03279081 COMPLETED
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
Tigenix S.A.U. n=568
NCT03905109 WITHDRAWN
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
Abivax S.A.
NCT02914600 TERMINATED
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Galapagos NV n=1,188
NCT03283085 COMPLETED
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Shire n=557
NCT03706456 COMPLETED
Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease
Takeda n=22
NCT06441526 COMPLETED
Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=94
NCT01277289 TERMINATED
Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
Quince Therapeutics S.p.A. n=51
NCT05104229 WITHDRAWN
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Stefan Holubar MD MS FACS, FASCRS
NCT02914561 COMPLETED
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Galapagos NV n=1,372
NCT03759288 TERMINATED
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
AstraZeneca n=89
NCT03945019 COMPLETED
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Celltrion n=396
NCT02772965 COMPLETED
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
University of North Carolina, Chapel Hill n=306
NCT03234907 COMPLETED
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
Takeda n=215
NCT02769494 WITHDRAWN
The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer
Xijing Hospital of Digestive Diseases
NCT03345849 COMPLETED
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
AbbVie n=526
NCT02394028 COMPLETED
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche n=1,035
NCT03345836 COMPLETED
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
AbbVie n=624
NCT03105128 COMPLETED
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
AbbVie n=931
NCT03104413 COMPLETED
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
AbbVie n=618
NCT02611817 COMPLETED
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Takeda n=644
NCT00790933 COMPLETED
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
Takeda n=2,243
NCT03627091 TERMINATED
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Shire n=40
NCT01453946 COMPLETED
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Padagis LLC n=55
NCT04643483 WITHDRAWN
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
UCB Biopharma SRL
NCT03566823 TERMINATED
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Shire n=34
NCT03559517 TERMINATED
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Shire n=30
NCT00989573 COMPLETED
A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease
Otsuka Pharmaceutical Co., Ltd. n=191
NCT03009396 COMPLETED
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
RedHill Biopharma Limited n=54
NCT02065570 COMPLETED
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
AbbVie n=514
NCT01951326 COMPLETED
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
RedHill Biopharma Limited n=331
NCT02680756 COMPLETED
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Shield Therapeutics n=250
NCT01352221 COMPLETED
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Shield Therapeutics n=128
NCT01496053 COMPLETED
Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)
Oslo University Hospital n=100
NCT03221166 TERMINATED
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
IRCCS Burlo Garofolo n=9
NCT02871635 COMPLETED
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Boehringer Ingelheim n=147
NCT03467620 WITHDRAWN
Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
University of Illinois at Chicago
NCT02038920 COMPLETED
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Takeda n=157
NCT01541579 COMPLETED
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
Tigenix S.A.U. n=278
NCT03357471 COMPLETED
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
UCB Biopharma S.P.R.L. n=70
NCT01692743 COMPLETED
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
University of Maryland, Baltimore n=348
NCT02240121 TERMINATED
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
Bausch Health Americas, Inc. n=80
NCT02240108 TERMINATED
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
Bausch Health Americas, Inc. n=81
NCT02596893 TERMINATED
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Celgene n=701
NCT01378390 TERMINATED
Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease
Tigenix S.A.U. n=56
NCT02641392 TERMINATED
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
Celgene n=310
NCT02499783 COMPLETED
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie n=205
NCT02255370 COMPLETED
Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease
University Hospital, Clermont-Ferrand n=61
NCT01986127 TERMINATED
Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients
Sara Varea n=26
NCT02185014 COMPLETED
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
AbbVie n=252
NCT02425111 COMPLETED
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Takeda n=101
NCT00552058 COMPLETED
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
UCB Pharma n=439
NCT00552344 COMPLETED
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
UCB BIOSCIENCES GmbH n=403
NCT00686374 COMPLETED
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
AbbVie (prior sponsor, Abbott) n=100
NCT02096861 COMPLETED
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Celltrion n=220
NCT01569503 TERMINATED
Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease
University Hospital, Grenoble n=9
NCT00764699 TERMINATED
Effect of Increlex® on Children With Crohn Disease
Nationwide Children's Hospital n=3
NCT01536418 TERMINATED
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
GlaxoSmithKline n=255
NCT01235689 COMPLETED
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
AbbVie (prior sponsor, Abbott) n=252
NCT02974322 WITHDRAWN
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Celgene
NCT01277666 COMPLETED
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
GlaxoSmithKline n=608
NCT01316939 TERMINATED
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
GlaxoSmithKline n=229
NCT01369342 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Janssen Research & Development, LLC n=640
NCT01369329 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Janssen Research & Development, LLC n=769
NCT01514240 COMPLETED
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
AstraZeneca n=123
NCT01562951 TERMINATED
Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa n=15
NCT01958827 COMPLETED
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
AbbVie n=28
NCT01190839 TERMINATED
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Janssen Biotech, Inc. n=297
NCT00783692 COMPLETED
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Millennium Pharmaceuticals, Inc. n=1,116
NCT01224171 COMPLETED
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Millennium Pharmaceuticals, Inc. n=416
NCT00944736 COMPLETED
Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease
Children's Mercy Hospital Kansas City n=12
NCT00989560 COMPLETED
Post-operative Crohn's Endoscopic Recurrence Study
University of Melbourne n=175
NCT00810030 COMPLETED
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
Vifor Pharma n=484
NCT00720538 COMPLETED
Thalidomide in Pediatric Inflammatory Bowel Diseases.
IRCCS Burlo Garofolo n=84
NCT01661257 COMPLETED
Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
Samsung Medical Center n=20
NCT00736983 COMPLETED
Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's
Foundation for Liver Research n=76
NCT00245505 TERMINATED
The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"
Ferring Pharmaceuticals n=3
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only